Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion of the conversation is that the user regrets not starting finasteride earlier to treat their hair loss. They are currently using dutasteride, oral minoxidil, and RU58841. Other users in the conversation express frustration with fearmongering about finasteride and emphasize the benefits of starting treatment early.

The conversation is about a user sharing their positive hair regrowth progress using 1mg oral finasteride and topical minoxidil. The user encourages others to try treatment early if they are unsure.

A trans man shared his 5-month progress using finasteride and minoxidil for temple regrowth, noting slow but steady results. Despite some negative comments, he received support and encouragement from others, with advice to start treatment early for best results.

The conversation is about a person using minoxidil, finasteride, estrogen, and bicalutamide to combat hair loss, expressing frustration and desperation over their situation. They are advised against using female hormones and encouraged to focus on finasteride and minoxidil, with suggestions to seek therapy for mental health support.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

Users discussed using treatments like minoxidil, finasteride, dutasteride, and exosomes for hair loss. They reported thicker hair and reduced shedding, with some experiencing minor side effects.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

User wants to mix finasteride into stemoxydine instead of minoxidil. Seeks stemoxydine brand recommendations for mixing in the UK.

A 21-year-old male is anxious about hair loss and its impact on marriage prospects. He has been using Minoxidil for 3 years, plans to start Finasteride in January 2023, and is also using Procapil and supplements.

The user is using finasteride 1mg every other day and seeks a topical solution to complement it, excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

A person was concerned about applying minoxidil and tretinoin in a public airport bathroom, fearing judgment from others. Most responses reassured them that no one cares, suggesting they apply it in a stall or skip a dose without worry.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.